Quick Summary
- Novo Nordisk cuts Wegovy prices 50% and Ozempic prices 35%.
- Effective January 1, 2027.
- Helps patients most impacted by high drug costs.
- Semaglutide is the only GLP-1 with multiple FDA approvals: Obesity, diabetes, kidney disease, and cardiovascular benefits.
- Part of broader access strategy.
Novo Nordisk announced a major reduction in US list prices for its semaglutide medications Wegovy, Ozempic, and Rybelsus. The new prices take effect January 1, 2027, with all three medications priced at $675 per month across all available doses.
This represents:
- 50% price reduction for Wegovy (from the current list price).
- 35% price reduction for Ozempic (from the current list price).
- Significant savings across the entire semaglutide product line.
Why This Matters?
Over 100 million Americans live with obesity, and more than 35 million have type 2 diabetes. Cost has been a major barrier preventing patients from accessing these life-changing medications.
Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices. Our actions today answer that call and remove cost barriers.
Learn MoreJamey Millar
What’s Being Reduced
Wegovy (for weight management)
- Available as: Injection 2.4 mg or oral tablets 25 mg.
- Price reduction: ~50%.
- New price: $675/month.
- FDA approved for: Adults with obesity, and those with comorbid cardiovascular disease.
Ozempic (for type 2 diabetes)
- Available as: Injection 0.5 mg, 1 mg, or 2 mg.
- Price reduction: ~35%.
- New price: $675/month.
- FDA approved for: Type 2 diabetes, chronic kidney disease, and those with comorbid cardiovascular disease.
Rybelsus (oral semaglutide for diabetes)
- Available as: Tablets 7 mg or 14 mg.
- New price: $675/month.
- FDA approved for: Type 2 diabetes management.
Who Benefits Most
The price reduction is specifically designed to help patients whose out-of-pocket costs are directly tied to list prices:
People with high-deductible health plans (HDHPs) — They typically pay a percentage of the list price until meeting their deductible
Patients with co-insurance coverage — Their copay is often a percentage of the list price (e.g., 20%)
Uninsured patients — Lower list prices reduce the reference price for patient assistance programs
Self-pay patients — Direct access to medications at more affordable rates
Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
Important Clarification About Pricing
The list price reduction does NOT change existing self-pay prices through NovoCare Pharmacy.
Here’s what’s happening:
| Pricing Type | What It Means | Status |
|---|---|---|
| List Price (WAC) | The reference price insurance companies use | ↓ DECREASING to $675 |
| Self-Pay Price | Price through NovoCare Pharmacy | UNCHANGED |
| Insurance Copay | What insured patients pay | Expected to DECREASE (based on lower list price) |
This means:
- Patients already getting medication through self-pay programs keep their current pricing
- Insured patients see reduced out-of-pocket costs due to the lower list price
- Everyone benefits, but in different ways
What Makes Semaglutide Different
Novo Nordisk emphasized that semaglutide is unique among GLP-1 medications because it has multiple FDA-approved uses:
Obesity Management
- Wegovy is specifically approved for adults with obesity.
- Also approved for patients with cardiovascular disease.
Diabetes Management
- Ozempic treats type 2 diabetes.
- Rybelsus is an oral tablet option for diabetes.
- Both are approved for patients with cardiovascular disease.
- Ozempic is also approved for chronic kidney disease.
Administration Options
- Injections: Once-weekly (convenient for busy patients).
- Oral tablets: Once-daily (for those who prefer not to inject).
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Why Did Novo Nordisk Make This Decision?
The company cited several key reasons:
1. Patient Demand Over 100 million Americans with obesity and 35 million with diabetes need access to effective treatment options.
2. Payer Feedback Insurance companies and healthcare systems have asked for lower prices to improve access.
3. Healthcare System Support Both private and public payers recognize the value but need pricing that makes sense for broader populations.
4. Clinical Value Semaglutide’s unique FDA approvals across multiple conditions justify its place in modern healthcare, even at lower prices.
5. Volume Strategy Lower prices mean more patients can access treatment, potentially increasing overall volume and market penetration.
Last Modified:
